Tag: CA48826D2014

Kelso Technologies Inc. Financial Results for the Three Months Ended June 30, 2025

WEST KELOWNA, British Columbia and BONHAM, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Kelso Technologies Inc. (“Kelso” or the “Company”) (TSX: KLS) reports that the Company has released the unaudited interim consolidated financial statements and Management Discussion and Analysis for the three months ended June 30, 2025.

Kelso Technologies Inc. Announces 2025 Annual General and Special Meeting Results

Kelso 2025 AGM shareholder voting results

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsCA48826D2014

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

MUSSO E80 Muse Sees Strong U.S. Sales Following European Breakout and MUSE Design Award Win

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026...

Tag: CA48826D2014

Kelso Technologies Inc. Financial Results for the Three Months Ended June 30, 2025

Kelso Technologies Inc. Announces 2025 Annual General and Special Meeting Results

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us